Benefit and danger from immunotherapy in myasthenia gravis

In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodolico, Carmelo, Nicocia, Giulia, Damato, Valentina, Antonini, Giovanni, Liguori, Rocco, Evoli, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861968/
https://www.ncbi.nlm.nih.gov/pubmed/33543421
http://dx.doi.org/10.1007/s10072-021-05077-6
_version_ 1783647185392369664
author Rodolico, Carmelo
Nicocia, Giulia
Damato, Valentina
Antonini, Giovanni
Liguori, Rocco
Evoli, Amelia
author_facet Rodolico, Carmelo
Nicocia, Giulia
Damato, Valentina
Antonini, Giovanni
Liguori, Rocco
Evoli, Amelia
author_sort Rodolico, Carmelo
collection PubMed
description In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
format Online
Article
Text
id pubmed-7861968
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78619682021-02-05 Benefit and danger from immunotherapy in myasthenia gravis Rodolico, Carmelo Nicocia, Giulia Damato, Valentina Antonini, Giovanni Liguori, Rocco Evoli, Amelia Neurol Sci Review Article In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated. Springer International Publishing 2021-02-05 2021 /pmc/articles/PMC7861968/ /pubmed/33543421 http://dx.doi.org/10.1007/s10072-021-05077-6 Text en © Fondazione Società Italiana di Neurologia 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Rodolico, Carmelo
Nicocia, Giulia
Damato, Valentina
Antonini, Giovanni
Liguori, Rocco
Evoli, Amelia
Benefit and danger from immunotherapy in myasthenia gravis
title Benefit and danger from immunotherapy in myasthenia gravis
title_full Benefit and danger from immunotherapy in myasthenia gravis
title_fullStr Benefit and danger from immunotherapy in myasthenia gravis
title_full_unstemmed Benefit and danger from immunotherapy in myasthenia gravis
title_short Benefit and danger from immunotherapy in myasthenia gravis
title_sort benefit and danger from immunotherapy in myasthenia gravis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861968/
https://www.ncbi.nlm.nih.gov/pubmed/33543421
http://dx.doi.org/10.1007/s10072-021-05077-6
work_keys_str_mv AT rodolicocarmelo benefitanddangerfromimmunotherapyinmyastheniagravis
AT nicociagiulia benefitanddangerfromimmunotherapyinmyastheniagravis
AT damatovalentina benefitanddangerfromimmunotherapyinmyastheniagravis
AT antoninigiovanni benefitanddangerfromimmunotherapyinmyastheniagravis
AT liguorirocco benefitanddangerfromimmunotherapyinmyastheniagravis
AT evoliamelia benefitanddangerfromimmunotherapyinmyastheniagravis

Ejemplares similares